| abstract |
REFERRING TO COMPOUNDS OF FORMULA I IN THE FORM OF SALT OR ZWITERIONIC WHERE R1 AND R3 ARE EACH A CARBOCICLIC GROUP C3-C15, HETEROCICLICO GROUP C5-C12; R2 IS H, HYDROXY, C1-C4 ALKYL; L AND M ARE EACH (A LINK AND -CH2-CH2-), (-CH2- AND -CH2-CH2-) OR (-CH2-CH2- AND -CH2-) RESPECTIVELY; J IS C1-C2 ALKYLENE, OR A LINK; R4 IS C1-C4 ALKYL; R5 IS C1-C10 ALKYL, HETEROCYCLIC FROM 5 TO 12 MEMBERS, C2-C10 ALKYL AMONG OTHERS. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION WITH PREVIOUS COMPOUNDS AS ACTIVE INGREDIENTS WHERE THE PREFERRED ARE: BROMIDE (1a, 1b) OF CIS AND TRANS-4- (2-HYDROXY-2,2-DIPHENYL-ACETOXI) -1-METHYL-1- (2-PHENOXY-ETHYL) -PIPERIDINIUM; (S) -2- (2-HYDROXY-2,2-DIPHENYL-ACETOXIMETHYL) -1-METHYL-1-OCT-2-YYL-PYRROLIDINIUM TRIFLUOROACETATE AND (1S / R, 3R) -3- (2) BROMIDE -HYDROXY-2,2-DIPHENYL-ACETOXY) -1-METHYL-1- (2-PHENOXY-ETHYL) -PIPERIDINIUM; AMONG OTHERS. SUCH COMPOUNDS ARE USEFUL IN THE TREATMENT OF CONDITIONS MEDIATED BY THE M3 MUSCARINIC RECEIVER |